Search research articles
Contact Us
Filters
Showing results (251-260 of 300) with videos related to
Page
of 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Leukemia & Lymphoma
|
April 8, 2025
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure
Emily Anderson, Yun Choi, Rachel J Buchsbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
British Journal of Haematology
|
September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
Catherine S Diefenbach, Hailun Li, Fangxin Hong, et al.
Blood Advances
|
November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Jonathan R Day, Melissa C Larson, Urshila Durani, et al.
British Journal of Haematology
|
December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2020
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
Daniel O Persky, Hongli Li, Deborah M Stephens, et al.
The Lancet. Haematology
|
December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
Kieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Leukemia & Lymphoma
|
January 11, 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis
Zeina Al-Mansour, Hongli Li, James R Cook, et al.
Page
of 30
Search research articles
Search
Showing results (251-260 of 300) with videos related to
Sort By:
Page
of 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Leukemia & Lymphoma
|
April 8, 2025
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure
Emily Anderson, Yun Choi, Rachel J Buchsbaum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2021
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.
British Journal of Haematology
|
September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era
Catherine S Diefenbach, Hailun Li, Fangxin Hong, et al.
Blood Advances
|
November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium
Jonathan R Day, Melissa C Larson, Urshila Durani, et al.
British Journal of Haematology
|
December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106
Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2020
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
Daniel O Persky, Hongli Li, Deborah M Stephens, et al.
The Lancet. Haematology
|
December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
Kieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Leukemia & Lymphoma
|
January 11, 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis
Zeina Al-Mansour, Hongli Li, James R Cook, et al.
Page
of 30